Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study

OBJECTIVE: The FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) trial assessed efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin in patients with knee osteoarthritis. Here, we report 5-year efficacy and safety results....

Descripción completa

Detalles Bibliográficos
Autores principales: Eckstein, Felix, Hochberg, Marc C, Guehring, Hans, Moreau, Flavie, Ona, Victor, Bihlet, Asger Reinstrup, Byrjalsen, Inger, Andersen, Jeppe Ragnar, Daelken, Benjamin, Guenther, Oliver, Ladel, Christoph, Michaelis, Martin, Conaghan, Philip G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Osteoarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292562/
https://www.ncbi.nlm.nih.gov/pubmed/33962962
http://dx.doi.org/10.1136/annrheumdis-2020-219181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292562/
https://www.ncbi.nlm.nih.gov/pubmed/33962962
http://dx.doi.org/10.1136/annrheumdis-2020-219181

Ejemplares similares